Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Managing Breast Cancer in Older Adults: An Updated International Policy Review
Can Serum Levels of Vitamin D at Diagnosis Predict Breast Cancer Prognosis?
Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer
FDA Brief: Trilaciclib Plus Chemotherapy Granted Fast Track Designation in Triple-Negative Breast Cancer
Early Results for Novel Combination in Metastatic Breast Cancer
Early-Phase Trials of Novel Antibody-Drug Conjugate in HER2-Overexpressed Solid Tumors
Pooled Analysis of HER2-Targeting Antibody-Drug Conjugate in Metastatic Breast Cancer
Fulvestrant With or Without Venetoclax in Locally Advanced or Metastatic Breast Cancer
Body Mass Index and Breast Cancer Outcomes by Racial Ancestry
Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer With Brain Metastases
ASCO 2021: Neoadjuvant Talazoparib Active in Germline BRCA1/2-Mutated HER2-Negative Breast Cancer
Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital
ASCO 2021: MONALEESA-3 Survival Update of Ribociclib/Fulvestrant for Advanced Breast Cancer
Updated ASCO Guideline for Managing Hereditary Breast Cancer
ASCO 2021: Long-Term Survival With Palbociclib Plus Fulvestrant in Advanced Breast Cancer
Treatment Implications of Breast Tumors’ Switch to HER2-Low Status in Recurrence
Implications of Symptom Burden Among Breast Cancer Survivors
ASCO 2021: Adjuvant Durvalumab Treatment for Triple-Negative Breast Cancer
ASCO 2021: Novel CDK4/6 Inhibitor Plus Fulvestrant Focus of Phase III Trial in Advanced Breast Cancer
ASCO 2021: Adjuvant Capecitabine Versus Platinum-Based Chemotherapy for Residual Triple-Negative Breast Cancer
ASCO 2021: COVID-19 Outcomes and Breast Cancer by Racial/Ethnic Group
Androgen Receptor–Targeting Agent Under Study in Metastatic Disease
ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer
ASCO 2021: OlympiA Trial of Adjuvant Olaparib After Chemotherapy for Early-Stage Breast Cancer
ESMO Breast 2021: Atezolizumab Plus Carboplatin for Metastatic Invasive Lobular Cancer
ESMO Breast 2021: Distinct Gene Signatures Associated With Pathologic Complete Response
ESMO Breast 2021: Does Clinical Benefit From Endocrine Therapy Differ by Risk Group?
Adding Oral Alisertib to Weekly Paclitaxel for Metastatic Breast Cancer
ESMO Breast 2021: Clinical Role of RAD51 Testing in Triple-Negative Breast Cancer
ESMO Breast 2021: Safety Outcomes With Abemaciclib Plus Endocrine Therapy in Early Breast Cancer
Eribulin and Pembrolizumab Combination in Triple-Negative Breast Cancer
ASBrS 2021: Can Medicaid Expansion Improve Disparities in Breast Reconstruction?
APHINITY Trial Update: Adjuvant Pertuzumab-Based Therapy in Early HER2-Positive Breast Cancer
Treadmill and T Cells: Can Exercise Enhance Immune Responses in Breast Cancer?
Can Healthy Plant-Based Diets Decrease the Risk of Breast Cancer?
Predicting Response to Combination Therapies for Breast Cancer Brain Metastases
AACR 2021: Can Gut Microbiota Influence Treatment Response in Metastatic Breast Cancer
Distant Lymph Node Metastases From Breast Cancer: A Regional Disease?
AACR 2021: Using ctDNA Changes to Predict Response to Palbociclib-Based Therapy for Breast Cancer
AACR 2021: Talazoparib/Carboplatin Under Study in Triple-Negative Breast Cancer
Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial
Could Regularly Drinking Sugar-Sweetened Soda Be Linked to Breast Cancer Mortality?
Is Surveillance Mammography Necessary in Older Breast Cancer Survivors?
AACR 2021: Neratinib Plus Fulvestrant for HER2-Mutant Metastatic Breast Cancer
FDA Brief: Cryoablation Technology Receives Breakthrough Device Designation in Breast Cancer
Are Type 2 Diabetes and Metformin Use Associated With Breast Cancer Risk?
Sacituzumab Govitecan-hziy Receives Regular FDA Approval for Triple-Negative Breast Cancer
FDA Grants Two New Breakthrough Device Designations for MRD Testing
Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel
KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancer
Risk of Breast Cancer in Common Drugs for Diabetes and Obesity
Endocrine Therapy for Men With Breast Cancer: Estradiol Levels, Sexual Function, and Quality of Life
Company Announces Discontinuation of Development of Oral Taxane Tesetaxel
Miami Breast Cancer Conference 2021: DESTINY-Breast01 Trial Update on Trastuzumab Deruxtecan-nxki
Miami Breast Cancer Conference 2021: Neratinib-Based Regimens for CNS Metastases
Are Most Women Who Forgo Reconstruction After Mastectomy Satisfied With the Results?
Miami Breast Cancer Conference 2021: Tolerability of Capecitabine in U.S. Patients With Triple-Negative Breast Cancer
Miami Breast Cancer Conference 2021: Comparing Radiolabeled Mapping Agents in Identifying Sentinel Lymph Nodes
Margetuximab-cmkb Versus Trastuzumab in ERBB2-Positive Advanced Breast Cancer
Miami Breast Cancer Conference 2021: Neoadjuvant Chemotherapy in Minority Groups
PD-L1 mRNA Expression and Treatment Response in Triple-Negative Breast Cancer
FDA Flags Safety Concerns for Oral Paclitaxel Plus Encequidar in Treatment of Breast Cancer
ASCO Guideline: Focus on Optimal Neoadjuvant Therapy for Breast Cancer
Can Androgen Receptor Agonists Improve Outcomes in Estrogen Receptor–Positive Breast Cancer?
Neoadjuvant Regimens Compared in Advanced Operable Breast Cancer
COVID-19 and Breast Cancer: Protective Role for Antiestrogen Therapies?
MONALEESA-7 Update: Ribociclib Plus Endocrine Therapy for Advanced Breast Cancer
Phase II Basket Trial of Dual HER2-Targeted Therapy in Metastatic Breast Cancer
World Health Organization Reports Breast Cancer Now the Most Common Type of Cancer Worldwide


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.